Advertisement
AXON vs RVMD
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Hold and RVMD is a Hold.
| AXON | RVMD | AXON / RVMD | |
| Capitalization | 36.4B | 40.9B | 89% |
| EBITDA | 406M | -1.69B | -24% |
| Gain YTD | -21.159 | 139.736 | -15% |
| P/E Ratio | 186.57 | N/A | - |
| Revenue | 3.22B | 0 | - |
| Total Cash | 693M | 3.94B | 18% |
| Total Debt | 1.83B | 642M | 286% |
AXON | RVMD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 86 Overvalued | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 68 | 2 | |
SMR RATING 1..100 | 81 | 98 | |
PRICE GROWTH RATING 1..100 | 65 | 35 | |
P/E GROWTH RATING 1..100 | 39 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AXON's Valuation (86) in the Biotechnology industry is in the same range as RVMD (95) in the null industry. This means that AXON’s stock grew similarly to RVMD’s over the last 12 months.
RVMD's Profit vs Risk Rating (2) in the null industry is significantly better than the same rating for AXON (68) in the Biotechnology industry. This means that RVMD’s stock grew significantly faster than AXON’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as RVMD (98) in the null industry. This means that AXON’s stock grew similarly to RVMD’s over the last 12 months.
RVMD's Price Growth Rating (35) in the null industry is in the same range as AXON (65) in the Biotechnology industry. This means that RVMD’s stock grew similarly to AXON’s over the last 12 months.
AXON's P/E Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for RVMD (100) in the null industry. This means that AXON’s stock grew somewhat faster than RVMD’s over the last 12 months.
| AXON | RVMD | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 81% | 3 days ago 86% |
| Momentum ODDS (%) | 3 days ago 71% | 3 days ago 75% |
| MACD ODDS (%) | 3 days ago 73% | 3 days ago 67% |
| TrendWeek ODDS (%) | 3 days ago 67% | 3 days ago 70% |
| TrendMonth ODDS (%) | 3 days ago 71% | 3 days ago 73% |
| Advances ODDS (%) | 7 days ago 75% | 7 days ago 82% |
| Declines ODDS (%) | 3 days ago 69% | 5 days ago 68% |
| BollingerBands ODDS (%) | 3 days ago 82% | 3 days ago 89% |
| Aroon ODDS (%) | 3 days ago 58% | 3 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green while RVMD’s FA Score has 1 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- RVMD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while RVMD’s TA Score has 5 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 6 bearish.
- RVMD’s TA Score: 5 bullish, 4 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -6.59% price change this week, while RVMD (@Biotechnology) price change was -6.29% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -1.22%. For the same industry, the average monthly price growth was -13.85%, and the average quarterly price growth was -6.62%.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.53%. For the same industry, the average monthly price growth was -8.46%, and the average quarterly price growth was +7.13%.
Reported Earning Dates
AXON is expected to report earnings on Nov 10, 2026.
RVMD is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Aerospace & Defense (-1.22% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (+1.53% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement